JP2017534652A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017534652A5 JP2017534652A5 JP2017525360A JP2017525360A JP2017534652A5 JP 2017534652 A5 JP2017534652 A5 JP 2017534652A5 JP 2017525360 A JP2017525360 A JP 2017525360A JP 2017525360 A JP2017525360 A JP 2017525360A JP 2017534652 A5 JP2017534652 A5 JP 2017534652A5
- Authority
- JP
- Japan
- Prior art keywords
- compound
- composition according
- leukemia
- pharmaceutically acceptable
- treatment
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000003839 salts Chemical class 0.000 claims description 34
- 150000001875 compounds Chemical class 0.000 claims description 28
- 208000032839 leukemia Diseases 0.000 claims description 11
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 9
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 claims description 6
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 claims description 6
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 claims description 6
- 208000031261 Acute myeloid leukaemia Diseases 0.000 claims description 4
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 claims description 4
- 239000008299 semisolid dosage form Substances 0.000 claims description 4
- 239000007909 solid dosage form Substances 0.000 claims description 4
- 230000037396 body weight Effects 0.000 claims description 2
- 239000002775 capsule Substances 0.000 claims description 2
- 239000007788 liquid Substances 0.000 claims description 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 2
- 239000006187 pill Substances 0.000 claims description 2
- 238000001959 radiotherapy Methods 0.000 claims description 2
- 238000011476 stem cell transplantation Methods 0.000 claims description 2
- 239000003826 tablet Substances 0.000 claims description 2
- 239000000203 mixture Substances 0.000 claims 9
- 125000001309 chloro group Chemical group Cl* 0.000 description 16
- 125000001153 fluoro group Chemical group F* 0.000 description 16
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 8
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 description 7
- 125000001246 bromo group Chemical group Br* 0.000 description 6
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 4
- 229910052739 hydrogen Inorganic materials 0.000 description 4
- 239000001257 hydrogen Substances 0.000 description 4
- 125000004435 hydrogen atom Chemical class [H]* 0.000 description 4
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 4
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 description 3
- 241000124008 Mammalia Species 0.000 description 3
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 3
- -1 methoxy, ethoxy Chemical group 0.000 description 3
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 3
- 241000699670 Mus sp. Species 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 description 1
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 description 1
- 0 CN(c1cccc(*)c1C(O)=C1C(N(*)c2ccccc2)=O)C1=O Chemical compound CN(c1cccc(*)c1C(O)=C1C(N(*)c2ccccc2)=O)C1=O 0.000 description 1
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 description 1
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 description 1
- 238000011579 SCID mouse model Methods 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000003651 drinking water Substances 0.000 description 1
- 235000020188 drinking water Nutrition 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP14193776.3 | 2014-11-19 | ||
| EP14193776 | 2014-11-19 | ||
| PCT/EP2015/075769 WO2016078921A1 (en) | 2014-11-19 | 2015-11-05 | Quinoline carboxamides for use in the treatment of leukemia |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017534652A JP2017534652A (ja) | 2017-11-24 |
| JP2017534652A5 true JP2017534652A5 (OSRAM) | 2018-12-06 |
| JP6715833B2 JP6715833B2 (ja) | 2020-07-01 |
Family
ID=51951635
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017525360A Active JP6715833B2 (ja) | 2014-11-19 | 2015-11-05 | 白血病の治療に使用するためのキノリンカルボキサミド |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US10300053B2 (OSRAM) |
| EP (1) | EP3180005B1 (OSRAM) |
| JP (1) | JP6715833B2 (OSRAM) |
| KR (1) | KR102525805B1 (OSRAM) |
| CN (1) | CN107072989B (OSRAM) |
| AU (1) | AU2015348778B2 (OSRAM) |
| BR (1) | BR112017009854B1 (OSRAM) |
| CA (1) | CA2967112C (OSRAM) |
| EA (1) | EA031643B1 (OSRAM) |
| ES (1) | ES2663836T3 (OSRAM) |
| IL (1) | IL252174B (OSRAM) |
| MX (1) | MX379401B (OSRAM) |
| NZ (1) | NZ732704A (OSRAM) |
| PL (1) | PL3180005T3 (OSRAM) |
| WO (1) | WO2016078921A1 (OSRAM) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2022010327A (es) | 2020-03-03 | 2022-11-09 | Active Biotech Ab | Tasquinimod o una sal farmaceuticamente aceptable del mismo para el uso en una terapia combinada. |
| EP4582448A3 (en) | 2020-07-23 | 2025-12-10 | Erasmus University Rotterdam Medical Center | S100 proteins as novel therapeutic targets in myeloproliferative neoplasms |
| JP2024503372A (ja) * | 2021-01-18 | 2024-01-25 | アクティブ バイオテック エイビー | 骨髄異形成症候群の処置における使用のためのタスキニモドまたはその薬学的に許容される塩 |
| BR112023023715A2 (pt) | 2021-05-25 | 2024-02-20 | Active Biotech Ab | Pluralidade de partículas compreendendo tasquinimod, composição farmacêutica, unidade de dosagem farmacêutica, uso da pluralidade de partículas ou da composição farmacêutica, e, método para o tratamento do câncer |
| JP2024524158A (ja) | 2021-07-02 | 2024-07-05 | アクティブ バイオテック エイビー | タスキニモドを含有する医薬製品および前記製品の純度を評価する方法 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE9801474D0 (sv) | 1998-04-27 | 1998-04-27 | Active Biotech Ab | Quinoline Derivatives |
| SE9802549D0 (sv) | 1998-07-15 | 1998-07-15 | Active Biotech Ab | Quinoline derivatives |
| SE0002320D0 (sv) * | 1999-10-25 | 2000-06-21 | Active Biotech Ab | Malignant tumors |
| SE0201778D0 (sv) | 2002-06-12 | 2002-06-12 | Active Biotech Ab | Process for the manufacture of quinoline derivatives |
| SE0400235D0 (sv) | 2004-02-06 | 2004-02-06 | Active Biotech Ab | New composition containing quinoline compounds |
| KR101855195B1 (ko) | 2010-07-09 | 2018-05-08 | 액티브 바이오테크 에이비 | 퀴놀린-3-카르복사미드의 제조 방법 |
| EP2537517A1 (en) * | 2011-06-22 | 2012-12-26 | Active Biotech AB | Deuterium-enriched 4-hydroxy-5-methoxy-n,1-dimethyl-2-oxo-n-[(4-trifluoro-methyl)phenyl]-1,2-dihydroquinoline-3-carboxamide |
| WO2015095833A1 (en) | 2013-12-20 | 2015-06-25 | Biomed Valley Discoveries, Inc. | Treatment of hematologic cancers |
-
2015
- 2015-11-05 AU AU2015348778A patent/AU2015348778B2/en active Active
- 2015-11-05 MX MX2017006110A patent/MX379401B/es unknown
- 2015-11-05 WO PCT/EP2015/075769 patent/WO2016078921A1/en not_active Ceased
- 2015-11-05 US US15/525,086 patent/US10300053B2/en active Active
- 2015-11-05 EP EP15790143.0A patent/EP3180005B1/en active Active
- 2015-11-05 JP JP2017525360A patent/JP6715833B2/ja active Active
- 2015-11-05 BR BR112017009854-7A patent/BR112017009854B1/pt active IP Right Grant
- 2015-11-05 NZ NZ732704A patent/NZ732704A/en unknown
- 2015-11-05 CA CA2967112A patent/CA2967112C/en active Active
- 2015-11-05 KR KR1020177015989A patent/KR102525805B1/ko active Active
- 2015-11-05 CN CN201580062750.4A patent/CN107072989B/zh active Active
- 2015-11-05 EA EA201791099A patent/EA031643B1/ru not_active IP Right Cessation
- 2015-11-05 ES ES15790143.0T patent/ES2663836T3/es active Active
- 2015-11-05 PL PL15790143T patent/PL3180005T3/pl unknown
-
2017
- 2017-05-09 IL IL252174A patent/IL252174B/en active IP Right Grant
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2015511609A5 (OSRAM) | ||
| ES2762250T3 (es) | Tratamiento combinado del cáncer | |
| JP2017534652A5 (OSRAM) | ||
| JP2016528301A5 (OSRAM) | ||
| JP2015505296A5 (OSRAM) | ||
| JP2016534063A5 (OSRAM) | ||
| JP2013542247A5 (OSRAM) | ||
| JP2019524883A5 (OSRAM) | ||
| JP2013501731A5 (OSRAM) | ||
| JP2016525121A5 (OSRAM) | ||
| JP2019515908A5 (OSRAM) | ||
| RU2014135436A (ru) | Комбинация ингибитора rtk с антиэстрогеном и ее применение для лечения рака | |
| JP2015524444A5 (OSRAM) | ||
| JP2017506624A5 (OSRAM) | ||
| JP2017528473A5 (OSRAM) | ||
| JP2016510326A5 (OSRAM) | ||
| NZ625592A (en) | Compositions and methods for the treatment of hepatic diseases and disorders | |
| JP2015522033A5 (OSRAM) | ||
| JP2019516739A5 (OSRAM) | ||
| JP2019520344A5 (OSRAM) | ||
| CN107108510B (zh) | 用于治疗多发性骨髓瘤的喹啉甲酰胺 | |
| JP2015517523A5 (OSRAM) | ||
| JP2013523740A5 (OSRAM) | ||
| JP2016537338A5 (OSRAM) | ||
| JP2015516419A5 (OSRAM) |